Revenue down 7.8% flipped PBT to a NZ$4.2m loss; leverage near 14x EBITDA

What changed

Revenue fell 7.8% to NZ$103.4m from NZ$112.1m. The more meaningful shift was at the profit line: PBT swung from NZ$5.8m to a NZ$4.2m loss, a NZ$10.0m reversal (-172.2%), and NPAT swung from NZ$4.2m to a NZ$3.2m loss (-176.7%). EBITDA for the half was NZ$6.1m, with no comparable disclosed. Trade debtors rose 13.7% to NZ$40.1m while total liabilities rose 23.6% against equity up just 1.2%, so the balance sheet expanded on the debt side. Cash ended at NZ$12.9m versus effectively nil (NZ$0.01m) a year earlier, but gross borrowings stand at NZ$98.7m, implying net debt of NZ$85.8m. The interim dividend was cut 60% to 1.0 cps from 2.5 cps.

What matters

• Operating profitability has broken down. Group EBITDA of NZ$6.1m supports net debt of NZ$85.8m only at roughly 14x leverage, and the NZ$10.0m PBT reversal on an 7.8% revenue decline points to meaningful operating deleverage rather than a pure top-line story. The modest NZ$1.0m inferred tax benefit does not rescue the read; on the analytical pass PBT is the cleaner earnings measure given the effective-tax-rate move from 28.1% to 23.5%.
• Working capital is absorbing cash. Receivable days stretched to 70.7 from 57.3 (a 13.4-day increase), and inventory sits at NZ$143.4m — approximately 252 days on the current revenue base. Against a shrinking revenue print, that inventory position is the single largest balance-sheet risk and the most likely future source of write-downs or margin pressure if it has to be cleared.
• Capital return has been re-sized. The 60% interim dividend cut is consistent with the loss and leverage profile and signals management has shifted priorities toward balance-sheet defence.

Expectations

No stated targets, forward-work disclosure, or full-year anchor were supplied, and there is no second-half shape context in the release. A naïve annualisation of HY24 revenue gives NZ$206.7m; whether the second half rebuilds margin is unaddressed in the extract. The release therefore does not support or refute a recovery path — it only establishes that the first half was loss-making on a lower revenue base with elevated inventory and debt.

Quality of result

Low. EBITDA of NZ$6.1m is already thin relative to a NZ$98.7m borrowing stack, and three factors undermine the quality of even that figure. First, receivable days lengthened by roughly 13 days, suggesting revenue recognition has outpaced collection. Second, inventory at 252 days of revenue is a large deferred cost sitting on the balance sheet that has not yet hit the P&L. Third, prior-period gross margin was 61.9%, but current gross margin is not disclosed in the supplied excerpts, so the extent of margin compression driving the PBT reversal cannot be quantified from this filing. Operating cash flow and capex were also not disclosed in the extract, so cash conversion cannot be tested directly — but the working-capital direction and the leverage math argue the headline EBITDA flatters the underlying cash picture.

Unresolved

• What is the current-period gross margin, and how much of the PBT reversal is price/mix versus volume versus cost of goods?
• What is operating cash flow for the half, and how much of the cash balance build reflects new drawings versus operating generation?
• Is any of the NZ$143.4m inventory aged or at risk of write-down, and what is the sell-through plan?
• What covenants sit against the NZ$98.7m of borrowings, and how much headroom exists at ~14x EBITDA leverage?
• Were there identifiable one-offs within the NZ$10.0m PBT swing, or is this a clean operating run-rate?

This briefing cannot assess cash generation, gross margin trajectory, or covenant headroom because operating cash flow, cost of sales, and debt terms were not disclosed in the supplied materials.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.